Drogueria MK LAB S.a.c

Drogueria MK LAB S.A.C., commonly known as MK LAB, is a Peruvian company specializing in the importation and commercialization of pharmaceutical products, particularly biologicals, blood derivatives, and biosimilars. Established in 2016, the company is headquartered in Surquillo, Lima, Peru. Its mission is to be the leading choice in the pharmaceutical sector, aiming to become strategic partners with clients, suppliers, and collaborators by offering quality products at the forefront of pharmaceutical science and technology. (mklab.pe)

MK LAB's product portfolio is divided into two main business lines: biological products and nutritional supplements. The company emphasizes efficiency, respect, trust, and responsibility in its operations, fostering an ethically professional environment. As of March 2025, MK LAB employed 16 individuals and engaged 7 service providers.

MK LAB operates multiple facilities to support its distribution network. The administrative office is located at Jr. Víctor Mantilla N° 237, Int. 1-3, Urb. Barrio Médico, Surquillo, Lima. The primary warehouse (Warehouse 1) is situated at Jr. Víctor Mantilla N° 245, 1st Floor, Urb. Barrio Surquillo, Surquillo, Lima, with storage services provided by Droguería ESKE CORPORATION S.A.C. An additional warehouse (Warehouse 2) is located at Av. Santa Ana, Urb. Primavera, Mz. A-31, Lote 40, Santa Anita, Lima. (digemid.minsa.gob.pe)

While specific details about MK LAB's logistics capabilities and geographic coverage beyond Lima are limited, the company's strategic partnerships with international laboratories in India, South Korea, and China suggest a robust supply chain capable of meeting national demand. (mklab.pe)

MK LAB functions primarily as a pharmaceutical importer and wholesaler in Peru's supply chain. By sourcing specialized pharmaceutical products from international suppliers, the company plays a crucial role in ensuring the availability of essential medications within the Peruvian market. Its focus on biologicals and biosimilars indicates a commitment to providing advanced therapeutic options to meet the evolving healthcare needs of the population. (mklab.pe)

MK LAB's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.1 million USD from India across 23 shipments. The top five imported products, including immunoglobulin and rituximab, account for 100% of the company's imports, indicating a portfolio entirely dependent on these items. This concentration suggests a strategic focus on specific high-demand therapeutic areas but also presents potential risks associated with supply chain disruptions or regulatory changes affecting these products.

The company's reliance on a limited number of suppliers—three verified Indian suppliers—raises questions about the stability and resilience of its supply chain. While the consistent sourcing from these suppliers may indicate strong relationships, the lack of diversification could expose MK LAB to vulnerabilities if any of these suppliers face operational challenges or regulatory issues.

MK LAB's supply chain resilience appears limited due to its concentrated sourcing from a few suppliers. The absence of backup suppliers and the focus on a narrow range of formulations suggest potential challenges in maintaining a steady supply of products. Additionally, the company's reliance on specific shipping routes and ports, such as the Port of Callao, could expose it to logistical disruptions. Ensuring compliance with international regulatory standards, including those set by the World Health Organization (WHO), is essential for maintaining product quality and uninterrupted supply.

MK LAB's concentrated sourcing strategy positions it as a specialized importer focusing on high-demand biologicals and biosimilars. This focus allows the company to establish expertise and strong relationships with key suppliers, potentially leading to favorable terms and priority access to products. However, the lack of diversification in its product portfolio and supplier base may limit its ability to adapt to market changes or respond to disruptions in the supply chain.

For Indian exporters, MK LAB represents a significant opportunity to penetrate the Peruvian market, especially in the biologicals and biosimilars segments. Establishing partnerships with MK LAB could facilitate access to a growing market segment, provided that exporters can meet the quality and regulatory standards required by Peruvian authorities.

In Peru, the Dirección General de Medicamentos, Insumos y Drogas (DIGEMID) is the primary regulatory authority overseeing the importation and commercialization of pharmaceutical products. DIGEMID is responsible for ensuring that imported medications comply with national health standards and regulations. Key legislation governing pharmaceutical imports includes the General Health Law and the Pharmaceutical Products Regulation, which outline the requirements for marketing authorization, quality control, and distribution of pharmaceutical products.

The marketing authorization pathway for Indian generics involves submitting a comprehensive dossier to DIGEMID, demonstrating compliance with Peruvian standards. This process includes providing evidence of Good Manufacturing Practice (GMP) certification, product stability data, and clinical efficacy studies. Approval from DIGEMID is mandatory before any pharmaceutical product can be marketed in Peru.

Import licensing in Peru requires importers to obtain authorization from DIGEMID, ensuring that all imported pharmaceutical products meet national health and safety standards. GMP certification is a critical component of this process; Peruvian authorities recognize certifications from reputable organizations such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certificates from these recognized bodies to facilitate the importation process.

Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within Peru. This authorization ensures that distributors adhere to regulatory standards concerning storage, handling, and transportation of medications.

Imported pharmaceutical products must undergo batch testing to confirm their quality, safety, and efficacy. Stability studies are also required to ensure that products maintain their intended quality throughout their shelf life under various storage conditions. Labeling requirements include providing information in Spanish, detailing the product's composition, dosage instructions, storage conditions, and expiration date. Serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, Peru implemented several regulatory changes affecting pharmaceutical imports. These include stricter requirements for GMP certification, enhanced scrutiny of import licenses, and updated labeling standards to improve product traceability. Additionally, there has been an increased emphasis on pharmacovigilance, requiring importers to establish systems for monitoring and reporting adverse drug reactions. These changes aim to strengthen the safety and efficacy of pharmaceutical products available in the Peruvian market.

MK LAB's focus on biologicals and biosimilars aligns with the growing demand for advanced therapeutic options in Peru. Biological products, including monoclonal antibodies like rituximab, offer targeted treatments for various conditions, while biosimilars provide cost-effective alternatives to expensive biologics. The importation of immunoglobulin addresses critical needs in immunodeficiency disorders. This strategic focus enables MK LAB to cater to specialized medical needs, positioning itself as a key player in the Peruvian pharmaceutical market.

MK LAB's sourcing strategy emphasizes importing finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, from India. This approach allows the company to offer ready-to-use products that meet international quality standards. India's robust pharmaceutical manufacturing sector, with its adherence to recognized GMP certifications, makes it a reliable source for these products. By focusing on finished formulations, MK LAB can streamline its supply chain and ensure timely delivery of products to the Peruvian market.

MK LAB serves the specialized segment of the Peruvian pharmaceutical market, focusing on the importation and distribution of biologicals and biosimilars. Its product mix indicates a commitment to providing advanced therapeutic options, positioning the company to serve hospitals, specialized clinics, and healthcare providers requiring these specific treatments. By concentrating on these high-demand areas, MK LAB differentiates itself from general pharmaceutical distributors, establishing a niche presence in the market.

There is a realistic opportunity for new Indian suppliers to collaborate with MK LAB, given the company's focus on importing biologicals and biosimilars. Suppliers that can provide high-quality, GMP-certified products in these categories may find a receptive partner in MK LAB. However, the existing concentration of MK LAB's sourcing suggests that any new supplier would need to offer compelling value propositions, such as competitive pricing, reliable supply chains, and adherence to Peruvian regulatory standards, to gain a foothold in the company's portfolio.

Indian exporters seeking to supply MK LAB and the Peruvian market must ensure that their products are manufactured in facilities holding valid GMP certifications recognized by Peruvian authorities, such